Download the Full Event Guide for Full Session Details.

• Discovery of a novel molecular glue degrader that simultaneously targets oncogenic KRAS mutants and CRAF, revealing a new strategy to disrupt MAPK signaling
• Engagement of a distinct E3 ligase not previously exploited in KRAS degradation, expanding the landscape beyond commonly used ligases like VHL or CRBN
• Demonstration of a dual degradation mechanism that supports the potential for broader therapeutic applications and highlights the power of molecular glues in targeted protein degradation